Magnesium compositions and uses thereof for neurological disorders
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/191
A23L-001/304
A61K-031/194
A61K-033/06
A61K-035/20
A61K-033/14
출원번호
US-0132980
(2013-12-18)
등록번호
US-9125878
(2015-09-08)
발명자
/ 주소
Liu, Guosong
Mao, Fei
출원인 / 주소
Magceutics, Inc.
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
3인용 특허 :
23
초록▼
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of application
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
대표청구항▼
1. A method of ameliorating the effects of a neurological disorder comprising administering to a subject an amount of magnesium-containing compound effective to increase a physiological concentration of magnesium by at least about 5% as compared to an initial level of magnesium prior to said adminis
1. A method of ameliorating the effects of a neurological disorder comprising administering to a subject an amount of magnesium-containing compound effective to increase a physiological concentration of magnesium by at least about 5% as compared to an initial level of magnesium prior to said administration, wherein in the magnesium-containing compound comprises magnesium threonate. 2. The method of claim 1, wherein said increase is measured under a fasting condition. 3. The method of claim 2, wherein said concentration of magnesium is measured after fasting for at least about twelve hours. 4. The method of claim 1, wherein said neurological disorder is dementia. 5. The method of claim 1, wherein said neurological disorder is Alzheimer's disease. 6. The method of claim 1, wherein said neurological disorder is depression. 7. The method of claim 1, wherein said physiological concentration is serum concentration, plasma concentration, or cerebrospinal fluid concentration. 8. The method of claim 1, wherein said magnesium threonate is a magnesium-counter ion complex. 9. The method of claim 1, wherein said magnesium-containing compound is a magnesium-supplemented foodstuff. 10. The method of claim 1, wherein said concentration is maintained for a period of greater than 4 months. 11. The method of claim 1, further comprising the step of determining starting physiological magnesium concentration of said subject under a fasting condition. 12. A method of therapeutic or prophylactic treatment of neurological disorder, comprising: administering to a subject in need of therapeutic or prophylactic treatment of said neurological disorder, a magnesium-containing composition to yield a sustained level of physiological concentration of magnesium of 0.75 mM or above for at least about 15 days, wherein the magnesium-containing composition comprises magnesium threonate. 13. The method of claim 12, wherein the composition of magnesium yields a sustained level of physiological concentration of magnesium of 0.75 mM or above for at least about 1 month. 14. The method of claim 12, wherein the composition of magnesium yields a sustained level of physiological concentration of magnesium of 0.75 mM or above for at least about 4 months. 15. The method of claim 12, wherein said neurological disorder is dementia. 16. The method of claim 12, wherein said neurological disorder is depression. 17. A method of therapeutic or prophylactic treatment of a neurological disorder comprising administering to a subject an amount of metal-organic counter ion complex effective to increase a physiological concentration of threonate by at least about 10% as compared to an initial level of threonate prior to said administration. 18. The method of claim 17, wherein said metal-organic counter ion complex comprises threonate as a counter-ion.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (23)
William T. Evans ; Dwight L. McKee, Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions.
George H. Clark ; Mary Ann Clark, Carbonated fortified milk-based beverage and method of making carbonated fortified milk-based beverage for the supplementation of essential nutrients in the human diet.
Yu Kai,CNX ; Wang Zhiwen,CNX ; Kou Fuping,CNX, L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof.
Skyler Jay S. (Key Biscayne FL) Frost Phillip (Miami Beach FL) Hahn Elliot F. (North Miami Beach FL), Method and composition for treatment of insulin resistance syndromes.
Glick J. Leslie (Potomac MD), Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory lo.
Atalla Rajai H. (Verona WI) Weinstock Ira A. (Madison WI) Hill Craig L. (Atlanta GA) Reiner Richard S. (Madison WI), Oxidation of lignin and polysaccharides mediated by polyoxometalate treatment of wood pulp.
Costa Jonathan L. (Wheaton IL) Diazgranados Jesus A. (Cali COX), Treatment of human diseases involving dysregulation or dysfunction of the nervous system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.